Targeted Therapy for Endometrial Cancer: Options and Evidence

What Is Targeted Therapy for Endometrial Cancer?

Targeted therapies are designed to attack cancer cells and spare your healthy cells. They target certain proteins or genes that are expressed in excess in cancer cells. They work best for aggressive types of uterine cancer. They are particularly helpful if the cancer has spread to other parts of your body or has come back after treatment.

How Does Targeted Therapy Differ From Chemotherapy?

Chemotherapy kills cells that grow quickly, such as cancer cells and healthy cells. This is why people tend to lose hair or become very ill. Targeted therapy looks for specific alterations in cancer cells, such as a particular protein or genetic alteration. Then it attacks just those cells. Your healthy cells are usually left alone. Targeted therapy tends to be easier on your body. You'll probably have fewer side effects than those that come with chemotherapy.

Targeted Therapy in Combination With Other Treatments:

Cancer treatment gives better results when targeted therapy is combined with other treatments. These treatments attack cancer in different ways. When combining targeted therapy with other treatments, cancer can be treated in multiple ways, rather than targeting the specific protein or gene. Some combined therapies after surgery may also reduce the size of tumors or eradicate remaining cancer cells.

How Do These Combination Therapies Work?

1. Chemotherapy + targeted treatments = anti-cancer effectiveness increased. Targeted agents enhance the action of chemotherapy upon cancer cells but also block the process that allows cancer cells to repair themselves from chemotherapy-induced damage.

2. Use of immunotherapy along with targeted treatments boosts your immune system's capability to combat cancer. Targeted agents inhibit signals that tumors use to develop and increase your immune system's ability to eliminate them.

3. Combining targeted therapy with surgery/radiation will cause tumors to undergo size reduction. When given in conjunction with surgery, targeted agents can reduce the size of a tumor so that it is easier for a surgeon to operate. After surgery, targeted agents will search for cancer cells that may remain undetected.

4. Combination targeted treatments = Block multiple tumor cell signaling pathways at the same time. Examples of this would be when there are resistant tumors to other available treatments.

Key Molecular Targets in Endometrial Cancer Therapy:

The molecular targets in endometrial cancer therapy are:

1. The PI3K (Phosphoinositide) / AKT (Protein Kinase 3) / mTOR (Mechanistic Target of Rapamycin) Pathway:

This pathway is mutated in many cancers of the endometrium. The cells are growing when they shouldn’t. This is done with drugs such as Everolimus or Temsirolimus. They essentially put the brakes on cell growth. These can be paired with hormone blockers to get better results.

2. Immunogenicity:

Many tumors possess defective DNA (deoxyribonucleic acid) repair mechanisms that make them much more immunogenic because they have mutations that result from this defect. Your body is then helped by immune checkpoint inhibitor (ICI) drugs such as Pembrolizumab and Dostarlimab to eliminate these types of cancers.

3. HER2 Overexpression (Human) Epidermal Growth Receptor:

A small percentage of aggressive types of malignancies produce excessive amounts of the HER2 protein. To address this problem, we use Trastuzumab, which blocks the HER2 signaling pathway to treat advanced (metastatic) breast cancer.

4. Vascular Endothelial Growth Factor (VEGF) or Angiogenesis:

It requires vascularization provided by blood vessels for solid tumors to grow and develop; therefore, blood supply can be blocked through the use of certain anticancer therapies or medications such as Lenvatinib or Bevacizumab. This type of treatment modality may provide better outcomes when combined with an immune checkpoint blockade.

5. Hormone Receptors:

Estrogen is food for some tumors. Hormone blockers work well, such as Letrozole or Tamoxifen. They are gentler treatments that many patients can tolerate well.

How Is Molecular Testing Done Before Targeted Therapy?

What is molecular testing, anyhow? It’s like hitting the bull’s-eye on your cancer’s armor. When a doctor looks at a person's tumor cells, they look at the DNA and proteins in the tumors to see if certain mutations exist that could be making the tumors grow. Once these mutations are identified, they can then prescribe a treatment designed to eliminate the tumors by targeting the specific problems identified in the patient's tumor.

The process can be broken down in the following way:

1. Sample Collection: To identify the possible mutations within a person's tumor, the doctor will first need to get a sample of the tumor by removing a piece of it from the body (that is, a biopsy).

• Tissue Biopsy: It is the most common method in which your doctor takes a sample of your tumor. It is the most reliable method.

• Liquid Biopsy: Much less invasive. Your doctor takes a bit of blood and looks for cancer DNA. The tumor cells shed DNA into your bloodstream.

• Normal Cell Sample: Sometimes your doctor will take a sample of your healthy cells (for example, from blood or saliva). This can tell you if the mutations are from the cancer or if you were born with them.

2. Laboratory Testing: Once your sample has been collected, a lab technician removes your DNA (or RNA/ribonucleic acid) from your cells and does various test methods to identify which mutations were found.

• Lab technicians use three key ways to test samples for mutations:

• Next-generation sequencing (NGS) allows the technician to test a lot of genes at one time.

• Immunohistochemistry (IHC) uses antibodies to find out what proteins are in your tissue.

• Fluorescence in situ hybridization (FISH) allows for the targeting of a specific DNA sequence by shining fluorescent light on that area.

3. A laboratory report with detailed information on the outcomes will be provided once testing has been completed.

What Are the Side Effects of Targeted Therapy in Endometrial Cancer?

The side effects of targeted therapy in endometrial cancer are as follows:

1. mTOR (mammalian target of Rapamycin) inhibitors' side effects include mouth sores, a dry and itchy rash, increased blood sugar levels, fatigue, and lowered white blood cells.

2. Angiogenesis inhibitors' side effects include diarrhea, nausea, vomiting, high blood pressure, mouth sores, an underactive thyroid gland, and a high amount of protein in the urine.

3. HER2 inhibitors' side effects include reduced heart pumping function, anemia, thrombocytopenia (low platelets), fever, chills, and shortness of breath.

Who Is Eligible for Targeted Therapy in Endometrial Cancer?

When do doctors use targeted therapy to treat endometrial cancer? These special treatments are for people primarily with:

• Cancer that has spread (advanced).

• Cancer that has returned.

• High-risk types.

Not everyone qualifies. Your doctor needs to test your tumor first to see if it has certain changes in its genes or proteins.

What Is the Prognosis and Response Rates With Targeted Therapy?

The prognosis and response rates with targeted therapy are:

When to Ask Your Oncologist About Targeted Therapy?

The ideal time to ask your oncologist (cancer specialist) about targeted therapy is as follows:

• Before starting any cancer treatment.

• If your cancer returns or spreads.

• If your current treatment is not effective.

• If your current treatment causes any side effects.

Conclusion

Targeted therapy is very effective for advanced endometrial cancer. Instead of giving everyone the same chemotherapy, your doctor may test your tumor's genes first to find exactly what'll work for you. Based on the finding, specific drugs that target those exact features are used. Drugs like Lenvatinib and immune therapies are helping patients live longer without their cancer getting worse.

If your doctor combines targeted drugs with immunotherapy, patients are living way longer than before. Before starting with targeted therapy, you should consult your cancer specialist.

Key Takeaways:

• Targeted therapy is used to treat advanced and recurrent endometrial cancer.

• When doctors add drugs like Trastuzumab to standard treatments, patients with aggressive types are living significantly longer.

• Many women get diagnosed too late, and these treatments can be hard on the body. That's why getting molecular testing done early makes such a difference; it helps doctors pick the right treatment from the start.

• If you're dealing with this diagnosis, consult a cancer specialist about advanced biomarker testing to find your best treatment path.